{"transactions":[{"id":1503413,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-23T19:30:40.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 22, 2025 or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":24000,"derivative":{"exercise_price":1.86,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000950170-24-064235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000095017024064235/ownership.xml","form_type":"4"}},{"id":1884259,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-19T16:23:52.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 17, 2024 or (ii) the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":12000,"derivative":{"exercise_price":2.52,"expiration_date":"2033-05-17","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-23-031002","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919123031002/doc4.xml","form_type":"4"}},{"id":1911212,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-04-28T16:54:51.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs fully vested one year from the grant date which was April 26, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs fully vested one year from the grant date which was April 26, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0001209191-23-026069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919123026069/doc4.xml","form_type":"4"}},{"id":1911211,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-28T16:54:51.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 6,305 shares received as a pro-rata distribution on September 28, 2021 (the \"Liquidating Distribution\") from CHP II, L.P., in which the Reporting Person is a managing partner. In prior reports, the reporting person reported beneficial ownership of 108,083 shares of aTyr Pharma common stock held by CHP II, L.P., which are no longer held as of September 28, 2021 due to the Liquidating Distribution."}],"balance_after":19797,"source":{"system":"sec-edgar","filing":"0001209191-23-026069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919123026069/doc4.xml","form_type":"4"}},{"id":2288643,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-04-28T19:39:09.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-22-026084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919122026084/doc4.xml","form_type":"4"}},{"id":2696696,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T21:05:25.000Z","date":"2021-05-21","kind":"sale","acquired":false,"shares":2500,"price":4.34,"value":10850.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. These shares were sold to cover fund expenses."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by CHP II, LLP (\"CHP\"). The general partner of CHP is CHP II Management, LLC, (\"CHP Management\"). The managing member of CHP Management, John Clarke, Brandon Hull and John Park, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by CHP. Each reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for Section 16 or any other purpose."}],"balance_after":108083,"source":{"system":"sec-edgar","filing":"0001209191-21-035836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919121035836/doc4.xml","form_type":"4"}},{"id":2735652,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-29T20:02:55.000Z","date":"2021-04-28","kind":"grant","acquired":true,"shares":1428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) April 28, 2022 or (ii) the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":1428,"derivative":{"exercise_price":4.21,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":1428},"source":{"system":"sec-edgar","filing":"0001209191-21-029117","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919121029117/doc4.xml","form_type":"4"}},{"id":3038843,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-03T21:47:52.000Z","date":"2020-09-02","kind":"sale","acquired":false,"shares":7260,"price":4.01,"value":29112.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"There shares are owned directly by CHP II, LLP (\"CHP\"). The general partner of CHP is CHP II Management, LLC, (\"CHP Management\"). The managing member of CHP Management, John Clarke, Brandon Hull and John Park, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by CHP. Each reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for Section 16 or any other purpose."}],"balance_after":110583,"source":{"system":"sec-edgar","filing":"0001209191-20-049578","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919120049578/doc4.xml","form_type":"4"}},{"id":3038842,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-03T21:47:52.000Z","date":"2020-08-28","kind":"sale","acquired":false,"shares":100,"price":4,"value":400.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"There shares are owned directly by CHP II, LLP (\"CHP\"). The general partner of CHP is CHP II Management, LLC, (\"CHP Management\"). The managing member of CHP Management, John Clarke, Brandon Hull and John Park, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by CHP. Each reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for Section 16 or any other purpose."}],"balance_after":117843,"source":{"system":"sec-edgar","filing":"0001209191-20-049578","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919120049578/doc4.xml","form_type":"4"}},{"id":3044464,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-28T21:09:52.000Z","date":"2020-08-27","kind":"sale","acquired":false,"shares":5440,"price":4.09,"value":22249.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.245, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"There shares are owned directly by CHP II, LLP (\"CHP\"). The general partner of CHP is CHP II Management, LLC, (\"CHP Management\"). The managing member of CHP Management, John Clarke, Brandon Hull and John Park, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by CHP. Each reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for Section 16 or any other purpose."}],"balance_after":117943,"source":{"system":"sec-edgar","filing":"0001209191-20-048698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919120048698/doc4.xml","form_type":"4"}},{"id":3044463,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-28T21:09:52.000Z","date":"2020-08-26","kind":"sale","acquired":false,"shares":2200,"price":4.296,"value":9451.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.245 to $4.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"There shares are owned directly by CHP II, LLP (\"CHP\"). The general partner of CHP is CHP II Management, LLC, (\"CHP Management\"). The managing member of CHP Management, John Clarke, Brandon Hull and John Park, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by CHP. Each reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for Section 16 or any other purpose."}],"balance_after":123383,"source":{"system":"sec-edgar","filing":"0001209191-20-048698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919120048698/doc4.xml","form_type":"4"}},{"id":3156105,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-08T16:48:26.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":1428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":1428,"derivative":{"exercise_price":3.65,"expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":1428},"source":{"system":"sec-edgar","filing":"0001209191-20-027949","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919120027949/doc4.xml","form_type":"4"}},{"id":3531347,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-10T17:01:08.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 8, 2020 or (ii) the Issuer's 2020 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":20000,"derivative":{"exercise_price":0.5834,"expiration_date":"2029-05-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-029005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919119029005/doc4.xml","form_type":"4"}},{"id":3885263,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2018-06-22T20:18:12.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9000,"derivative":{"exercise_price":105.26,"exercise_date":"2019-06-20","expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001735276-18-000028","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000028/edgardoc.xml","form_type":"4"}},{"id":3908645,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2018-06-04T20:25:45.000Z","date":"2018-05-31","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2018."}],"balance_after":0,"derivative":{"exercise_price":27.28,"exercise_date":"2009-06-03","expiration_date":"2018-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001735276-18-000006","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000006/edgardoc.xml","form_type":"4"}},{"id":3908644,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-04T20:25:45.000Z","date":"2018-05-31","kind":"sale","acquired":false,"shares":100,"price":101.97,"value":10197.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2018."}],"balance_after":8891,"source":{"system":"sec-edgar","filing":"0001735276-18-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000006/edgardoc.xml","form_type":"4"}},{"id":3908643,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-04T20:25:45.000Z","date":"2018-05-31","kind":"sale","acquired":false,"shares":2100,"price":101.37,"value":212877.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sales prices ranged from $100.97 to $101.88."}],"balance_after":8991,"source":{"system":"sec-edgar","filing":"0001735276-18-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000006/edgardoc.xml","form_type":"4"}},{"id":3908642,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-04T20:25:45.000Z","date":"2018-05-31","kind":"sale","acquired":false,"shares":10042,"price":100.33,"value":1007513.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sales prices ranged from $99.92 to $100.90."}],"balance_after":11091,"source":{"system":"sec-edgar","filing":"0001735276-18-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000006/edgardoc.xml","form_type":"4"}},{"id":3908641,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-04T20:25:45.000Z","date":"2018-05-31","kind":"sale","acquired":false,"shares":2758,"price":99.38,"value":274090.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sales prices ranged from $98.89 to $99.75."}],"balance_after":21133,"source":{"system":"sec-edgar","filing":"0001735276-18-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000006/edgardoc.xml","form_type":"4"}},{"id":3908640,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-04T20:25:45.000Z","date":"2018-05-31","kind":"exercise","acquired":true,"shares":15000,"price":27.28,"value":409200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2018."}],"balance_after":23891,"source":{"system":"sec-edgar","filing":"0001735276-18-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000006/edgardoc.xml","form_type":"4"}},{"id":3927635,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-17T16:16:43.000Z","date":"2018-05-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 15, 2019 or (ii) the Issuer's 2019 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":20000,"derivative":{"exercise_price":1.35,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-030884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919118030884/doc4.xml","form_type":"4"}},{"id":4291298,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2017-06-06T20:55:41.000Z","date":"2017-06-02","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11250,"derivative":{"exercise_price":71.99,"exercise_date":"2018-06-02","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001553878-17-000022","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000022/edgardoc.xml","form_type":"4"}},{"id":4324446,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":90657,"kind":"person","name":"CLARKE JOHN K","position":1,"cik":"0001219015","reported_name":"CLARKE JOHN K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-11T18:49:45.000Z","date":"2017-05-09","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors."}],"balance_after":20000,"derivative":{"exercise_price":3.15,"expiration_date":"2027-05-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-031633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219015/000120919117031633/doc4.xml","form_type":"4"}}]}